Lbp Am Sa Sells 7,530 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

LBP AM SA cut its holdings in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 3.5% in the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 205,305 shares of the biopharmaceutical company's stock after selling 7,530 shares during the quarter. LBP AM SA's holdings in Gilead Sciences were worth $23,004,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. Bridgewater Associates LP grew its position in shares of Gilead Sciences by 122.7% in the 4th quarter. Bridgewater Associates LP now owns 460,936 shares of the biopharmaceutical company's stock valued at $42,577,000 after purchasing an additional 253,994 shares during the period. Nissay Asset Management Corp Japan ADV grew its position in shares of Gilead Sciences by 5.2% in the 4th quarter. Nissay Asset Management Corp Japan ADV now owns 284,243 shares of the biopharmaceutical company's stock valued at $26,750,000 after purchasing an additional 14,009 shares during the period. Golden State Wealth Management LLC grew its position in shares of Gilead Sciences by 14.5% in the 1st quarter. Golden State Wealth Management LLC now owns 863 shares of the biopharmaceutical company's stock valued at $97,000 after purchasing an additional 109 shares during the period. Ontario Teachers Pension Plan Board grew its position in shares of Gilead Sciences by 54.6% in the 4th quarter. Ontario Teachers Pension Plan Board now owns 37,051 shares of the biopharmaceutical company's stock valued at $3,422,000 after purchasing an additional 13,086 shares during the period. Finally, Mufg Securities Americas Inc. acquired a new position in shares of Gilead Sciences in the 4th quarter valued at approximately $1,699,000. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Gilead Sciences Price Performance

Shares of GILD traded up $2.18 during trading hours on Wednesday, hitting $113.24. 5,234,322 shares of the company were exchanged, compared to its average volume of 7,689,193. The company has a quick ratio of 1.23, a current ratio of 1.37 and a debt-to-equity ratio of 1.16. Gilead Sciences, Inc. has a fifty-two week low of $66.34 and a fifty-two week high of $119.96. The company has a market cap of $140.86 billion, a price-to-earnings ratio of 23.84, a P/E/G ratio of 0.72 and a beta of 0.29. The firm's fifty day moving average is $107.26 and its 200 day moving average is $104.29.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share for the quarter, topping the consensus estimate of $1.77 by $0.04. Gilead Sciences had a return on equity of 51.93% and a net margin of 20.76%. The business had revenue of $6.67 billion during the quarter, compared to the consensus estimate of $6.77 billion. During the same period in the prior year, the company earned ($1.32) EPS. Gilead Sciences's revenue for the quarter was down .3% on a year-over-year basis. On average, equities analysts anticipate that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, June 27th. Investors of record on Friday, June 13th were given a dividend of $0.79 per share. The ex-dividend date of this dividend was Friday, June 13th. This represents a $3.16 annualized dividend and a dividend yield of 2.79%. Gilead Sciences's dividend payout ratio is currently 66.53%.

Analysts Set New Price Targets

Several equities research analysts have commented on the company. Oppenheimer cut their target price on Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating on the stock in a research note on Friday, April 25th. Morgan Stanley upped their price objective on Gilead Sciences from $130.00 to $135.00 and gave the stock an "overweight" rating in a research note on Friday, April 25th. Needham & Company LLC reiterated a "hold" rating on shares of Gilead Sciences in a research note on Wednesday, May 21st. Cantor Fitzgerald initiated coverage on Gilead Sciences in a research note on Tuesday, April 22nd. They set an "overweight" rating and a $125.00 price objective on the stock. Finally, JPMorgan Chase & Co. upped their price objective on Gilead Sciences from $120.00 to $130.00 and gave the stock an "overweight" rating in a research note on Thursday, March 27th. Nine equities research analysts have rated the stock with a hold rating, fourteen have issued a buy rating and three have given a strong buy rating to the stock. According to MarketBeat.com, Gilead Sciences currently has an average rating of "Moderate Buy" and a consensus target price of $111.38.

Insider Buying and Selling

In related news, insider Johanna Mercier sold 3,000 shares of the company's stock in a transaction on Monday, June 16th. The stock was sold at an average price of $110.17, for a total transaction of $330,510.00. Following the completion of the sale, the insider directly owned 120,168 shares in the company, valued at $13,238,908.56. This represents a 2.44% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Daniel Patrick O'day sold 10,000 shares of the stock in a transaction dated Monday, June 30th. The shares were sold at an average price of $110.45, for a total value of $1,104,500.00. Following the completion of the transaction, the chief executive officer owned 615,725 shares of the company's stock, valued at $68,006,826.25. This represents a 1.60% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 58,500 shares of company stock worth $6,340,745 in the last ninety days. 0.27% of the stock is owned by insiders.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.